London-headquartered virtual fertility service Apricity has secured £14.7 million in Series B funding, which will be used to finance the firm’s expansion within the UK and internationally.
The company, which was founded in 2018, is planning to launch in Spain later this year and will then target Germany and Italy. The funding will also be used to enable the company to drive its ongoing growth in the UK and to further develop its technology.
Apricity’s technology, which is offered by UK employee benefits providers including AXA and Rewards Gateway, provides users with personalised support during fertility treatment via an app. According to the firm, its fertility has a success rate of 46 per cent, with the UK average standing at 31 per cent.
The new funding, which follows a £5.1 million Series A round the company completed in June 2019, was led by Swiss healthcare investor MTIP, with support from Spanish fund Iris Ventures.
Apricity founder and CEO Caroline Noublanche commented: “We look forward to supporting more women and couples across Europe who are struggling to conceive and can now hope for a better, less stressful alternative option.”
MTIP Managing Partner Christoph Kausch said: “Rather than focusing on just one part of the fertility journey, Apricity is using cutting-edge technology to transform the end-to-end experience for patients and has seen incredibly strong traction as a result.”
Iris Ventures founder and Managing Partner Montse Suarez added: “There is no doubt Apricity is a stand-out in their field, using patient-centric technology to make a real impact in the lives of fertility patients, delivering high-quality care when and where patients need it most.”
